ArticleFrontiers in public health2025
Neck pain burden in China and G20 countries: an analysis of 1990-2021 with a 30-year forecast for China.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Efficacy of Fu's Subcutaneous Needling for chronic non-specific neck pain and its effect on muscle elasticity: a randomized controlled trial.Frontiers in medicine · 2025Trial
- [Analysis of current status and trends of disease burden of neck pain in China from 1990 to 2023].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Article
- The burden of hypertensive heart disease in China and G20 countries: analysis from 1990 to 2021 and 30-year projections for China.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neck pain (NP) represents a significant global public health challenge and is the fourth leading cause of disability in China and among G20 nations. Given the accelerating trends of population ageing and shifts in contemporary lifestyles, the burden of NP is likely to increase, necessitating urgent, comprehensive analysis and the formulation of effective interventions. Objectives and methods: This study utilizes the 2021 Global Burden of Disease (GBD) database to extract data concerning the incidence, prevalence, DALY rate, ASIR, ASPR, ASDR, and other relevant metrics of noncommunicable diseases in China and G20 countries from 1990 to 2021. The analysis is conducted via the R programming language, with joinpoint regression employed to calculate the APC and AAPC. Additionally, an ARIMA model is utilized to forecast the incidence rate in China over the next 30 years. Results: In 2021, China reported 10.29 million (95% UI: 8.06-13.03 million) incident cases and 48.37 million (37.66-60.06 million) prevalent cases of NP. The ASIR, ASPR, and ASDR were estimated at 567 (448-699) per 100,000 population, 2,549 (2,007-3,141) per 100,000 population, and 254 (166-357) per 100,000 population, respectively. Among G20 countries, NP affected 28.71 million (22.50-35.54 million) incident cases and 137.66 million (109.04-169.31 million) prevalent cases, with corresponding ASIR, ASPR, and ASDR values of 507 (398-617) per 100,000 population, 2,362 (1,856-2,892) per 100,000 population, and 234 (156-334) per 100,000 population, respectively. The analysis revealed no statistically significant changes in the AAPCs of the ASIR and ASPR for either China or the G20 countries from 19,902,021. Notably, women consistently presented higher ASIR and ASPR values than men did across all the studied populations. Projection models indicate that by 2051, NP incidence rates will remain stable for China and men, whereas women's rates are anticipated to significantly decline. Conclusion: The global community must prioritize the burden of NP and promote precision diagnosis and prevention. Policies should balance technological innovation with social support, strengthen legislative protection for high-risk occupations and harsh climates, implement personalized interventions, and reduce the burden at its root.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.